Improvement in Verbal Fluency and Aphasia in Alzheimer's Disease with Etanercept
Author Information
Author(s): Edward L Tobinick, Hyman Gross
Primary Institution: Institute for Neurological Research, Los Angeles, USA
Hypothesis
Perispinal etanercept has the potential to improve verbal function in Alzheimer's disease.
Conclusion
The study suggests that perispinal etanercept may lead to rapid and sustained improvements in verbal fluency and related language functions in Alzheimer's disease.
Supporting Evidence
- All neuropsychological measures showed significant improvement except for two tests.
- Improvements were noted within minutes of etanercept administration.
- Results suggest the need for larger scale studies and Phase 3 trials.
Takeaway
This study shows that a medicine called etanercept can help people with Alzheimer's disease talk better, and it works really fast.
Methodology
A prospective, single-center, open-label pilot study where 12 patients received weekly perispinal etanercept for six months.
Potential Biases
Potential bias due to the open-label design and small sample size.
Limitations
The study was open-label and not controlled, limiting the strength of the conclusions.
Participant Demographics
Patients with mild-to-severe Alzheimer's disease.
Statistical Information
P-Value
0.0007
Statistical Significance
p < 0.0007
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website